Maze Therapeutics, Inc.
MAZE
$7.83
$0.233.03%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -100.00% | -96.97% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -100.00% | -96.97% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -100.00% | -96.97% | |||
| SG&A Expenses | 9.28% | 14.19% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.21% | 0.00% | |||
| Operating Income | -22.69% | -143.44% | |||
| Income Before Tax | -19.27% | -146.23% | |||
| Income Tax Expenses | 1.43% | -132.33% | |||
| Earnings from Continuing Operations | -19.50% | -146.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.50% | -146.46% | |||
| EBIT | -22.69% | -143.44% | |||
| EBITDA | -23.80% | -141.36% | |||
| EPS Basic | -101.83% | -144.03% | |||
| Normalized Basic EPS | -25.84% | -138.63% | |||
| EPS Diluted | -131.12% | -162.81% | |||
| Normalized Diluted EPS | -25.84% | -153.46% | |||
| Average Basic Shares Outstanding | 0.15% | 2.70% | |||
| Average Diluted Shares Outstanding | 0.15% | -25.78% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
